Among the clinical drugs used in the treatment of type 2 diabetes mellitus, thiazolidinediones, such as rosiglitazone (Ros) and pioglitazone, can be used as PPARγ agonists to significantly reduce hypoglycemia and improve the sensitivity to the insulin pathway. The gene discussed is INS; the disease is Hypoglycemia.